tbuckley/cabot-search huggingface dataset:
Coverage and Access for Americans With Chronic Disease Under the Affordable Care Act
Authors: Hugo Torres, Elisabeth Poorman, Uma Tadepalli, Cynthia Schoettler, Chin Ho Fung, Nicole Mushero, Lauren Campbell, Gaurab Basu, Danny McCormick
Journal: Annals of Internal Medicine (2017)

Half of Americans have at least 1 chronic disease. Many in this group, particularly racial/ethnic minorities, lacked insurance coverage and access to care before the Patient Protection and Affordable Care Act (ACA) was enacted.To determine whether the ACA has had an effect on insurance coverage, access to care, and racial/ethnic disparities among adults with chronic disease.Quasi-experimental policy intervention.Nationally representative, noninstitutionalized sample in the United States.606 277 adults aged 18 to 64 years with a chronic disease.Implementation of ACA provisions on 1 January 2014.Self-reported insurance coverage, having a checkup, having a personal physician, and not having to forgo a needed physician visit because of cost.After the ACA was implemented, insurance coverage increased by 4.9 percentage points (95% CI, 4.4 to 5.4), not having to forgo a physician visit increased by 2.4 percentage points (CI, 1.9 to 2.9), and having a checkup increased by 2.7 percentage points (CI, 2.2 to 3.4). Having a personal physician did not change (0.3 percentage points [CI, -0.2 to 0.8]). All outcomes varied considerably by state, and coverage increased more in states that expanded Medicaid. Although racial/ethnic minorities had greater improvements in some outcomes, approximately 1 in 5 black and 1 in 3 Hispanic persons with a chronic disease continued to lack coverage and access to care after ACA implementation.The study examined data from only the first year of the ACA's major coverage expansion provisions.Although the ACA increased coverage and access for persons with chronic disease, substantial gaps remain, particularly for minorities and those in Medicaid nonexpansion states.None.
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
Authors: Chiara Berlato, Moddasar N. Khan, Tiziana Schioppa, Richard Thompson, Eleni Maniati, Anne Montfort, Maryam Jangani, Monica Canosa, Hagen Kulbe, Urs B. Hagemann, Alexander R. Duncan, Laura Fletcher, Robert W. Wilkinson, Thomas Powles, Sergio A. Quezada, Frances R. Balkwill
Journal: Journal of Clinical Investigation (2017)

Elevated expression of the chemokine receptor CCR4 in tumors is associated with poor prognosis in several cancers. Here, we have determined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed abnormal levels of CCR4 ligands in RCC patient plasma. An antagonistic anti-CCR4 antibody had antitumor activity in the RENCA mouse model of RCC. CCR4 inhibition did not reduce the proportion of infiltrating leukocytes in the tumor microenvironment but altered the phenotype of myeloid cells, increased NK cell and Th1 cytokine levels, and reduced immature myeloid cell infiltrate and blood chemokine levels. In spite of prominent changes in the myeloid compartment, the anti-CCR4 antibody did not affect RENCA tumors in T cell-deficient mice, and treatment with an anti-class II MHC antibody abrogated its antitumor activity. We concluded that the effects of the anti-CCR4 antibody required the adaptive immune system and CD4+ T cells. Moreover, CCL17-induced IFN-γ production was reduced when Th1-polarized normal CD4+ T cells were exposed to the CCR4 ligand, evidencing the involvement of CCR4 in Th1/Th2 regulation. The anti-CCR4 antibody, alone or in combination with other immune modulators, is a potential treatment approach to human solid cancers with high levels of CCR4-expressing tumor-infiltrating leukocytes and abnormal plasma CCR4 ligand levels.
Stromal Cell-Derived Secreted Factors Contribute to the Innate Imatinib Resistance of Leukemia Stem Cells In a Genetically Defined Murine Model of Chronic Myeloid Leukemia Blast Crisis
Authors: C. Ronald Geyer, Michael Szeto, Ashton Craven, Marciano D. Reis, David P. Sheridan, John F. DeCoteau
Journal: Blood (2010)
Degranulation of T-Cells Specific for the CMV-Proteins pp65 and IE-1 in Allogeneic Stem Cell Recipients.
Authors: Susanne S. Ganepola, Stephan S. Fuhrmann, Lutz L. Uharek, Eckhard E. Thiel, Hans Dieter H.D. Volk, Florian F. Kern
Journal: Blood (2006)
A Local Versus Centralized Processing Comparison of Plasma Cell Isolation, Viability, and RNA Integrity.
Authors: Gregory J. Ahmann, Kimberly J. Henderson, Tammy L. Price-Troska, Michael M. Timm, Rempel Rachel, Roberta W. DeGoey, Christy M. Finke, Angela Dispenzieri, Philip R. Greipp, Alicia Sable-Hunt, Leif Bergsagel, Rafael Fonseca
Journal: Blood (2005)
Heterotopic liver retransplantation for impossible former graft explantation
Authors: Daniel Azoulay, Eylon Lahat, Chady Salloum, Philippe Compagnon, Cyrille Feray
Journal: Hepatology (2017)

Azoulay, Daniel; Lahat, Eylon; Salloum, Chady; Compagnon, Philippe; Feray, Cyrille Author Information
The Role of Efferocytosis in Atherosclerosis
Authors: Yoko Kojima, Irving L. Weissman, Nicholas J. Leeper
Journal: Circulation (2017)

The necrotic core has long been a hallmark of the vulnerable atherosclerotic plaque. Although apoptotic cells are cleared quickly in almost all other tissue beds, their removal appears to be significantly impaired in the diseased blood vessel. Emerging evidence indicates that this phenomenon is caused by a defect in efferocytosis, the process by which apoptotic tissue is recognized for engulfment by phagocytic cells such as macrophages. Genetic and experimental data suggest that efferocytosis is impaired during atherogenesis caused by dysregulation of so-called eat me ligands, which govern the edibility of cells undergoing programmed cell death. The following is a summary of recent data indicating that efferocytosis is a major unappreciated driver of lesion expansion but also a reversible defect that can potentially be targeted as a means to prevent plaque progression.
Efficacy of the Combination of Gemtuzumab-Ozogamicin (Mylotarg(R)) and Cytarabine (GOCYT) in Childhood Myeloid Leukemia: A Compassionate Use Based Review in France.
Authors: Benoit Brethon, Karima Yakouben, Caroline Oudot, Patrick Boutard, Benedicte Bruno, Cecile Jerome, Brigitte Nelken, Lionel de Lumley, Yves Bertrand, Jean-Hugues Dalle, Thierry Leblanc, Andre Baruchel
Journal: Blood (2006)
Array CGH As a Complementary Tool in the Diagnosis of Myelodysplastic Syndromes
Authors: María Abáigar, Eva Lumbreras, Irene Rodríguez, Javier Sánchez-del-Real, María Díez-Campelo, Rebeca Cuello, Jose M Alonso, Isabel Recio, Javier García Frade, Lourdes Hermosin, Juan N Rodríguez, Marta Megido, Magdalena Sierra, Guillermo Martín-Núñez, Tomás González, Manuel Vargas, Jose L Fuster, Pilar Giraldo, Jesús M Hernández, Jesús F San Miguel
Journal: Blood (2012)
Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity.
Authors: Myron S. Czuczman, Marion Skipper, Alice Mohr, Zale P. Bernstein, Francisco J. Hernandez-Ilizaliturri, Asher A. Chanan-Khan
Journal: Blood (2007)
HCP-01DIAGNOSIS AND MANAGEMENT OF HIGH-GRADE GLIOMA IN PATIENTS WITH HIV
Authors: Nattasha Acevedo, Cinthi Pillai, Mary Welch
Journal: Neuro-Oncology (2015)

BACKGROUND: While opportunistic infections and lymphoma are common causes of a brain mass in immunosuppressed patients with HIV, primary brain tumor is more likely in those with CD4 counts > 500 cells/mm3. Small series have noted a higher than expected frequency of high-grade glioma (HGG) in HIV patients, but they remain rare with fewer than 40 cases reported. This study adds 4 from an inner city population. METHODS: Retrospective case series. Chart review. RESULTS: Four patients were identified – 3 women with GBM and 1 man with anaplastic astrocytoma (AA). Median age at tumor diagnosis was 57.5 (range 48-66). All patients were on HAART at time of diagnosis and median CD4 count was 516 cells/mm3 (range 359-888 cells/mm3). For 3 patients with available data, median time between HIV and HGG diagnoses was 5 years (range 2-8). Median time from presentation to HGG diagnosis was 34 days (range 9-59). At presentation, HGG was considered the most likely diagnosis for all GBM patients; differential for the AA patient included low-grade glioma, infectious or inflammatory process. Three patients underwent CSF sampling to investigate alternate diagnoses. Empiric toxoplasmosis therapy was initiated in 1, but stopped after 4 days. All patients underwent subtotal resection followed by chemo-radiation with temozolomide (TMZ). No patient required dose reduction for hematological toxicity. One experienced a drop in CD4 count to 29 cells/mm3 despite undetectable viral load. Two patients received therapy at recurrence; agents included bevacizumab and irinotecan. Three died (OS range 4-17 months); 1 remains alive 22 months from diagnosis. CONCLUSIONS: HGG should be a strong diagnostic consideration in immune-competent HIV patients presenting with brain mass. Additional testing for toxoplasmosis and lymphoma is low-yield and should not delay surgical diagnosis. Treatment for HGG in such patients should be the same as the general population.
Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia
Authors: Tapan Kadia, Farhad Ravandi, Naval Daver, Gautam Borthakur, Jorge E. Cortes, Elias Jabbour, Steven M. Kornblau, Srdan Verstovsek, William Wierda, Jan A Burger, Zeev Estrov, Courtney DiNardo, Xiao Qin Dong, Naveen Pemmaraju, Maro Ohanian, Koichi Takahashi, Stephany Hendrickson, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2015)
Patient, Provider, and Combined Interventions for Managing Osteoarthritis in Primary Care
Authors: Kelli D. Allen, Eugene Z. Oddone, Cynthia J. Coffman, Amy S. Jeffreys, Hayden B. Bosworth, Ranee Chatterjee, Jennifer McDuffie, Jennifer L. Strauss, William S. Yancy, Santanu K. Datta, Leonor Corsino, Rowena J. Dolor
Journal: Annals of Internal Medicine (2017)

Background: A single-site study showed that a combined patient and provider intervention improved outcomes for patients with knee osteoarthritis, but it did not assess separate effects of the interventions. Objective: To examine whether patient-based, provider-based, and patient–provider interventions improve osteoarthritis outcomes. Design: Cluster randomized trial with assignment to patient, provider, and patient–provider interventions or usual care. (ClinicalTrials.gov: NCT01435109) Setting: 10 Duke University Health System community-based primary care clinics. Participants: 537 outpatients with symptomatic hip or knee osteoarthritis. Intervention: The telephone-based patient intervention focused on weight management, physical activity, and cognitive behavioral pain management. The provider intervention involved electronic delivery of patient-specific osteoarthritis treatment recommendations to providers. Measurements: The primary outcome was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score at 12 months. Secondary outcomes were objective physical function (Short Physical Performance Battery) and depressive symptoms (Patient Health Questionnaire). Linear mixed models assessed the difference in improvement among groups. Results: No difference was observed in WOMAC score changes from baseline to 12 months in the patient (−1.5 [95% CI, −5.1 to 2.0]; P = 0.40), provider (2.5 [CI, −0.9 to 5.9]; P = 0.152), or patient–provider (−0.7 [CI, −4.2 to 2.8]; P = 0.69) intervention groups compared with usual care. All groups had improvements in WOMAC scores at 12 months (range, −3.7 to −7.7). In addition, no differences were seen in objective physical function or depressive symptoms at 12 months in any of the intervention groups compared with usual care. Limitations: The study involved 1 health care network. Data on provider referrals were not collected. Conclusion: Contrary to a previous study of a combined patient and provider intervention for osteoarthritis in a Department of Veterans Affairs medical center, this study found no statistically significant improvements in the osteoarthritis intervention groups compared with usual care. Primary Funding Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing
Authors: Lorenzo Melchor, John R Jones, Oleg Lenive, Erich Allen Peterson, Annamaria Brioli, Alex Murison, Christopher P Wardell, Martin F Kaiser, Paula Proszek, Eileen Mary Boyle, Dil B Begum, Charlotte Pawlyn, David C Johnson, Inmaculada Rapado, David A Cairns, Walter M Gregory, Roger G Owen, Graham H Jackson, Mark T Drayson, Faith E Davies, Joaquín Martínez-López, Richard S Houlston, Mel Greaves, Brian A Walker, Gareth J Morgan
Journal: Blood (2015)
Comparison of 4 Previously Established, but Highly Different Comorbidity Scores (Kaplan Feinstein Index [KF], Charlson-Comorbidity Index [CCI], Satariano Index [SI], Hematopoietic cell transplantation-specific comorbidity index [HCT-CI]) Identifies the KF and HCT-CI as Most Relevant, but Use of An Easily Applied 3-Risk-Factor (KLeber) -Score Suggests to Even More Effectively Predict Progression-Free- and Overall-Survival Differences in Multiple Myeloma (MM) Patients (pts).
Authors: Meike Terhorst, Martina Kleber, Gabriele Ihorst, David De Pasquale, Monika Engelhardt
Journal: Blood (2009)
Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study.
Authors: A. J. Armstrong, G. Kemeny, J. D. Turnbull, C. Chao, C. Winters, Y. A. Fesko, D. A. Bradley, S. Halabi, D. J. George, M. Garcia-Blanco
Journal: Journal of Clinical Oncology (2010)

TPS249 Background: Currently, the survival of men who have failed docetaxel-based chemotherapy for metastatic CRPC is poor, on the order of 12-14 months, and for men with an elevated CTC count, this figure is even further reduced. Two of the principal molecular mechanisms of progression to the castrate-resistant state include loss of the PTEN tumor suppressor pathway and alterations in androgen receptor signaling through mutation or amplification. These pathways contribute to increased PI3K/mTOR signaling and AR-dependent signaling, respectively, which leads to progressive tumor growth, survival, treatment resistance, and metastasis. Based on this rationale, we are conducting a single arm phase II study of the mTOR inhibitor temsirolimus (Torisel) in combination with anti-androgen therapy, in order to assess the clinical activity of this combination on disease progression and changes in PSA and CTC counts. This trial is funded by the NCCN. Methods: Eligible men will have metastatic progressive CRPC based on RECIST, bone scan, or PSA criteria and are required to have a CTC count ≥10 cells per 7.5 mL whole blood as measured by standard Cellsearch methods. Prior chemotherapy is allowed. Men must have resolution of prior grade 2 toxicities and be at least 2 weeks from completion of palliative radiation, 4 weeks from prior systemic therapies, have adequate organ function (WBC≥3K, ANC≥1.5K, platelets≥75L, Hgb≥9 g/dl, Cr ≤2.0xULN, AST/ALT ≤2.5xULN, normal bilirubin), and have a KPS≥60. Patients with serious underlying cardiovascular, autoimmune, pulmonary, or other medical comorbidities are excluded. Patients will initially receive temsirolimus 25 mg IV weekly at Duke University, and upon PSA/CTC progression, an anti-androgen will be added. The combination will be continued until progression defined by PCWG2 criteria. PSA, LDH, imaging, CTC count, and changes in CTC biology including measures of epithelial plasticity and genomic signatures will be measured every 8 weeks. The primary endpoint is the proportion of men with a favorable CTC count conversion to <5 cells/7.5 mL over time. 1/20 patients have been accrued as of December 2009. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis, Wyeth/Pfizer Novartis, Wyeth/Pfizer Novartis, Wyeth/Pfizer
Does obesity affect the outcome of renal cell carcinoma?
Authors: Mohammad Mozayen, Anteneh Tesfaye, Khalil Katato
Journal: Journal of Clinical Oncology (2012)

444 Background: Obesity has been associated with increased risk of renal cell carcinoma (RCC). However the prognostic significance of obesity in the survival of patients with RCC is still undefined. Our study examined prognostic significance of obesity on the overall survival of patients (pts) with RCC in community hospital settings. Methods: A retrospective review of pts diagnosed with RCC between 1995 and 2008 in a community hospital setting was done. Pts with additional malignancies, lymphoma of the kidneys and no follow up data were excluded from the study. Demographics, body mass index(BMI) at diagnoses, pathology, disease stage, operative note, and subsequent follow up data were reviewed. The WHO BMI classification was used to group pts into Underweight (UW) &lt; 18.5; Normal (NL): 18.5-24.99; Pre-obese (PO): 25-29.99; Obese I (Ob I): 30-34.99; Obese II (Ob II): 35-39.99; Obese III (Ob III): ≥40. The primary outcome was 3 years overall survival. Results: A total Of 205 pts reviewed, 127 (62.3%) were males, 176 (85.9%) were Caucasians. The median age of the study population was 65 (22-91). The prevalence of obesity was 42.3% in the study population; 46.2% in females and 39% in males (p=0.19). The median BMI was 28.8 (16-54.6). Pts were categorized based on their BMI as: UW (1.5%), NL (21.4%), PO (34.7%), Ob I (26%), Ob II (8.2%), and Ob III (8.2%). Clear Cell was the commonest histology (79%). Stage I was seen in 53.9%, II in 23.5%, III in 13.7% and IV in 8.8% of the study population. The 3 year overall survival for the study population was 67.3% (95% CI: 60.4-73.7). The 3-year overall survival of obese and non obese pts with RCC were 66.4% and 69.5% respectively (p=0.34). There was no difference in the 3-year overall survival of patient in the BMI groupings: (UW: 66.7%, NW: 59%, Pre-Ob: 70.6%, Obese I: 70%, II: 75%, III: 62.5%; p=0.8). Conclusions: Our study didn’t find any association between BMI and 3 year overall survival in pts with RCC. Larger randomized trials are warranted before excluding the negative impact of obesity in the overall survival of pts with renal cell carcinoma.
Chronic Lymphocytic Leukemia B-Cells Lack or Express Markedly Reduced Levels of the Phosphatase PHLPP, Which Regulates B-Cell Receptor Induced AKT Activation.
Authors: Mirza Suljagic, Luca Laurenti, Muhammad Alam, Pablo G Longo, Sami N Malek, Dimitar G Efremov
Journal: Blood (2008)
Genomic Determinants of Human Fetal and Adult Erythroid Gene Expression
Authors: Jian Xu, Zhen Shao, Kimberly Glass, Daniel E. Bauer, Luca Pinello, Ben Van Handel, Serena Hou, John A. Stamatoyannopoulos, Hanna K. A. Mikkola, Guo-Cheng Yuan, Stuart H. Orkin
Journal: Blood (2012)
Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75
Authors: Jeffrey E. Lancet, Jorge E. Cortes, Donna E. Hogge, Martin Tallman, Tibor Kovacsovics, Lloyd E. Damon, Ellen Ritchie, Rami S. Komrokji, Arthur C. Louie, Eric J Feldman
Journal: Blood (2010)
Lymphocyte Surface Molecule Expression on Basal State and After Challenge: Association of Clinical Profile, Inflammation, Hematological and Biochemical Markers in Sickle Cell Anemia Patients
Authors: Bruno A. V. Cerqueira, Wendell Vilas-Boas, Angela Zanette, Jorge Clarencio, Marco Salvino, Rodrigo Cezar, Daniela Andrade, Mitermayer Reis, Marilda Goncalves
Journal: Blood (2011)
FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal cancer: A GERCOR randomized phase III study (MIROX).
Authors: Mohamed Hebbar, Benoist Chibaudel, Thierry Andre, Laurent Mineur, Denis Smith, Christophe Louvet, Jean Luc Dutel, Marc Ychou, Jean-Louis Legoux, May Mabro, Dominique Auby, David Brusquant, Ahmed Khalil, Stephanie Truant, Alexandra Hadengue, Franck Bonnetain, Francois-Rene Pruvot, Cecile Dalban, Aimery De Gramont
Journal: Journal of Clinical Oncology (2012)

3506 Background: Perioperative FOLFOX4 is the standard chemotherapy (CT) in patients with resectable metastases from colorectal cancer (CRC) (Nordlinger et al, Lancet 2008). To increase curability and reduce the risk of severe neuropathy, we evaluated the sequential administration of a dose-dense oxaliplatin-based regimen followed by an irinotecan-based regimen. Methods: Patients with CRC and initially resectable or resected metastases were randomized between arm A (control): FOLFOX4 (12 cycles; oxaliplatin 85 mg/m²) or arm B (investigational): FOLFOX7 (6 cycles; oxaliplatin 130 mg/m²) followed by FOLFIRI (6 cycles; irinotecan 180 mg/m²). CT was either perioperative or postoperative. Stratification criteria were: perioperative vs. postoperative CT, surgery alone vs. radiofrequency ablation +/- surgery, Blumgart’s prognostic score (0-1 vs. 2-3 vs. 4-5). Only one metastatic site was allowed, but the number of metastases per organ was not limited. The primary endpoint was disease-free survival (DFS). Results: From May 2004 to June 2010, 284 patients were randomized (142 in each arm). Baseline patient characteristics were similar in both arms. Liver was the main metastatic site. There was only one metastasis in 70 (49.3%) patients in arm A and 69 (48.6%) patients in arm B. CT was administered perioperatively in 168 (59.1%) patients, and postoperatively in 116 (40.9%) patients. In case of perioperative CT, R0-R1 resection was achieved in 58/85 (68.2%) patients in arm A and 67/83 (80.7%) patients in arm B. Grade 3 neuropathy occurred in 34 (23.9%) and 28 (20.0%) patients in arm A and B, respectively. Grade 3/4 thrombocytopenia and gastrointestinal toxicities (nausea, vomiting, diarrhea) were more frequent in arm B. Median follow-up was 50.4 months [95% CI: 45.6-54.4]. Median DFS were 22.4 months [95% CI: 17.9-36.2] in arm A and 23.0 months [95% CI: 19.7-35.6] in arm B (HR=0.97 [95% CI: 0.72-1.31]; p=.856). Conclusions: FOLFOX7 followed by FOLFIRI is not superior to the standard FOLFOX4 chemotherapy in patients with resectable metastatic colorectal cancer.
First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)
Authors: Daruka Mahadevan, Mark C Lanasa, Maria Whelden, Susan J Faas, Terrie L Ulery, Anjli Kukreja, Lan Li, Camille L Bedrosian, Leonard T Heffner
Journal: Blood (2010)
Safety, Feasibility, and Cost-Effectiveness with Outpatient Administration of High-Dose Cytarabine Consolidation in Acute Myeloid Leukemia
Authors: Gene A. Wetzstein, Jeffrey E. Lancet, Jennifer E. Kallner, Jeffrey M. Sivik, Viet Q. Ho, Timothy J. George, Sheetal Desai, Shanel Fisher, Michael D. Newton, Alan F. List
Journal: Blood (2008)
Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia
Authors: Kevin R Kelly, Kelli Oberheu, Ernest Medina, Claudia M Espitia, Devalingam Mahalingam, Pietro Taverna, Gavin S. Choy, Steffan T Nawrocki, Francis J. Giles, Jennifer S Carew
Journal: Blood (2010)